SLC2A1 and rheumatoid arthritis: Thus, tofacitinib, an oral Janus kinase inhibitor for the treatment of RA, decreases in RA synoviocytes [100] and CD8+ T cells [114] the mRNA expression of different glycolysis rate-limiting enzymes such as the mentioned HK2, PFKFB or other molecules involved in aerobic glycolysis, as GLUT1, also higher in RA synoviocytes, which in turn results in the attenuation of inflammatory response and hyperplasia state.